by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Eli Lilly and Company Warning Letter Details

Warning Letter

Eli Lilly and Company

Lilly Corporate Center Indianapolis , IN 46285 United States

Issue DateSeptember 09, 2025

FEI NumberN/A

Violations2

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

False & Misleading Claims/Misbranded

Eli Lilly and Company FDA Warning Letter, September 9, 2025